Literature DB >> 1646073

Epstein-Barr virus-associated lymphoproliferative syndromes: studies in two European families.

V Schuster1, E Dohrmann, H W Kreth.   

Abstract

The X-linked lymphoproliferative syndrome (XLP), also known as Duncan's disease, is an X-linked recessive disorder that is characterized by the inability of affected individuals to mount a sufficient immune response to Epstein-Barr virus (EBV). After EBV primary infection, male family members suffer from severe infectious mononucleosis (IM), aplastic anemia, hypogammaglobulinemia, and a spectrum of lymphoproliferative diseases. Autosomal mode of inheritance with similar symptoms as in XLP has been reported. We have studied two families with EBV-associated syndromes and an X-linked and an autosomal mode of inheritance, respectively. Affected family members presented with severe IM, hemophagocytosis, aplastic anemia, acquired hypogammaglobulinemia, and B-cell lymphoproliferative diseases.

Entities:  

Mesh:

Year:  1991        PMID: 1646073

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  4 in total

1.  Molecular genetic haplotype segregation studies in three families with X-linked lymphoproliferative disease.

Authors:  V Schuster; S Seidenspinner; T Grimm; W Kress; S Zielen; M Bock; H W Kreth
Journal:  Eur J Pediatr       Date:  1994-06       Impact factor: 3.183

2.  Animal models of virus-induced neurobehavioral sequelae: recent advances, methodological issues, and future prospects.

Authors:  Marco Bortolato; Sean C Godar
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-05-18

Review 3.  Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects.

Authors:  V Schuster; H W Kreth
Journal:  Eur J Pediatr       Date:  1992-10       Impact factor: 3.183

Review 4.  Quantitative genetics in the study of virus-induced disease.

Authors:  Martin T Ferris; Mark T Heise
Journal:  Adv Virus Res       Date:  2014       Impact factor: 9.937

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.